These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

212 related items for PubMed ID: 1898888

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Mode of suppression of pituitary and gonadal function after acute or prolonged administration of a luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN, Wakefield G, Schlechter NL, Lindner J, Souza KH, Kamilaris TC, Konidaris S, Rivier JE, Vale WW, Toglia M.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):446-54. PubMed ID: 2537334
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL, Monroe SE, Marshall LA, Fluker MR, Nerenberg CA, Jaffe RB.
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [Abstract] [Full Text] [Related]

  • 6. Hormonal effects of single gonadotropin-releasing hormone antagonist doses in men.
    Jockenhövel F, Bhasin S, Steiner BS, Rivier JE, Vale WW, Swerdloff RS.
    J Clin Endocrinol Metab; 1988 May; 66(5):1065-70. PubMed ID: 3129447
    [Abstract] [Full Text] [Related]

  • 7. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man.
    Salameh W, Bhasin S, Steiner BS, McAdams LA, Peterson M, Rivier JE, Vale WW, Swerdloff RS.
    J Androl; 1994 May; 15(1):22-8. PubMed ID: 8188535
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Single subcutaneous doses of a luteinizing hormone-releasing hormone antagonist suppress serum gonadotropin and testosterone levels in normal men.
    Pavlou SN, Debold CR, Island DP, Wakefield G, Rivier J, Vale W, Rabin D.
    J Clin Endocrinol Metab; 1986 Aug; 63(2):303-8. PubMed ID: 3088019
    [Abstract] [Full Text] [Related]

  • 10. Comparison of the antigonadotropic activity of three GnRH antagonists (Nal-Glu, Antide and Cetrorelix) in a non-human primate model (Macaca fascicularis).
    Weinbauer GF, Nieschlag E.
    Andrologia; 1993 Aug; 25(3):141-7. PubMed ID: 8517553
    [Abstract] [Full Text] [Related]

  • 11. Suppression of plasma gonadotropins and testosterone in adult male monkeys (Macaca fascicularis) by a potent inhibitory analog of gonadotropin-releasing hormone.
    Adams LA, Bremner WJ, Nestor JJ, Vickery BH, Steiner RA.
    J Clin Endocrinol Metab; 1986 Jan; 62(1):58-63. PubMed ID: 3079603
    [Abstract] [Full Text] [Related]

  • 12. Effective suppression of luteinizing hormone and testosterone by single doses of the new gonadotropin-releasing hormone antagonist cetrorelix (SB-75) in normal men.
    Behre HM, Klein B, Steinmeyer E, McGregor GP, Voigt K, Nieschlag E.
    J Clin Endocrinol Metab; 1992 Aug; 75(2):393-8. PubMed ID: 1639941
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders.
    Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2394-403. PubMed ID: 7543113
    [Abstract] [Full Text] [Related]

  • 18. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists.
    Hall JE, Whitcomb RW, Rivier JE, Vale WW, Crowley WF.
    J Clin Endocrinol Metab; 1990 Feb; 70(2):328-35. PubMed ID: 2105329
    [Abstract] [Full Text] [Related]

  • 19. Suppression of pituitary-gonadal function by a potent new luteinizing hormone-releasing hormone antagonist in normal men.
    Pavlou SN, Wakefield GB, Island DP, Hoffman PG, LePage ME, Chan RL, Nerenberg CA, Kovacs WJ.
    J Clin Endocrinol Metab; 1987 May; 64(5):931-6. PubMed ID: 3104388
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.